Kornimate/medical-research-clean huggingface dataset:
computerized based analysis for detection and severity assessment of stuttering

Conditions: Stuttering

Summary: in the light of previous attempts to design and develop automated and objective measures for automatic speech recognition system that detects disfluent speech and assess its severity, yet fully automated measurement of stuttered speech is not available. this study was triggered by the need to design and develop a simple and reliable computerized tool for identification of stuttering and measurement for its severity. therefore, the aim of this study is to develop a user interface that can work on windows system for the adopted stuttering recognition model which can be used in clinical practice by physicians and therapists.

stuttering is a speech disorder in which the normal flow of speech is disrupted by occurrences of dysfluencies, such as repetition, prolongations and blocks (1). features that have been found to differ between stutterers and nonstutterers are rate of speech and frequency of dysfluent utterances (2). an arabic version of stuttering severity instrument (a-ssi) is used to assess the stuttering severity in it, the overall severity score of stuttering is measured by combining the scores of percentages of stuttered syllables (%ss), mean duration of the three longest stuttering events (mdtlse), and physical concomitants (pc) (3). the subjective assessment methods of stuttering are; time-consuming, prone to error, subjective (4), so it is better to automate the measurement of disfluencies using speech recognition technologies and computational intelligence (5). speech recognition executes a task similar to what the human brain undertakes (6). stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition (7). the speech signals are pre-processed (8), and certain features are extracted from them by signal processing techniques, e.g. mell frequency cepstral coefficients (mfcc) (9). (mfcc) is considered the most popular used feature extraction technique (10). the classification process contains two steps; training and testing (11). in training process, data is labeled based on the classes and a model is learned. in testing phase: the model is tested and computed the accuracy, sensitivity, and specificity of the classification models (11). finally, stuttering from non-stuttering speech will be recognized and separated (5) also to assess the severity of stuttered speech.

Eligibility criteria:
inclusion criteria: 1. age: from 10 to 30 years old. 2. gender: both sexes will be included in the study. 3. the participants in the study group suffering from developmental stuttering (stuttering symptoms was of early childhood onset, intermittent course and dated since early childhood) seeking speech therapy 4. have language aptitudes coping with his or her chronological age. exclusion criteria: * 1. presence of any other speech or language disorders. 2. mental retardation. 3. poor scholastic performances. 4. presence of any psychiatric or neurologic disorders.
oral health recovery group

Conditions: Oral Health; Dental Care; Psychiatric Diagnosis

Summary: the aim of the study is to test a brief, peer-led group-based oral health educational intervention - called the "oral health recovery group" - designed for individuals with psychiatric disabilities.

participants at each site will obtain either: a) a peer-led oral health recovery educational group, representing the primary intervention; or b) viewing of an educational video about oral health, representing the comparison intervention. after participating in either condition, an onsite peer staff member will offer to help the participant make a dentist appointment. they will follow up with the participant as needed for a two-month period to help arrange dental care and follow up on any dental self-care goals established by the participant, such as purchasing toothpaste with fluoride.

Eligibility criteria:
inclusion criteria: * an adult member/consumer with the selected site (jimho or washtenaw cmh) * ability to understand and willingness to read a consent terms handout and discussion * participant must understand/read/speak english exclusion criteria: * not a member/consumer with the site * not able to understand and/or not willing to read consent terms handout * does not understand/read/speak english
study to evaluate the safety of a bivalent vaccine of new 6:2 influenza virus reassortants in healthy adults

Conditions: Influenza

Summary: this study is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (flumist) containing them.

the primary study objective is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (flumist) containing them. safety will be demonstrated by similar fever rates (oral temperature ≥101°f days 0-7) in vaccine and placebo recipients.

Eligibility criteria:
inclusion criteria: * 18-49 years of age (not yet reached their 50th birthday); * in good health; * available by telephone; * ability to understand and comply with the requirements of the protocol; and * signed informed consent and hipaa authorization. exclusion criteria: * any condition for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical follow-up or hospitalization during the preceding year; * acute febrile (\>100.0°f oral) and/or respiratory illness, including cough or sore throat, within the 14 days prior to enrollment; * hypersensitivity to egg or egg protein; * hypersensitivity to gentamicin; * any known immunosuppressive condition or immune deficiency disease, including hiv infection, or ongoing immunosuppressive therapy; * history of guillan-barré syndrome; * household contact who is immunocompromised (participant should also avoid close contact with immunocompromised individuals for at least 21 days); * participation in another investigational trial within 30 days prior to enrollment or expected enrollment in another investigational trial during this study; * chronic or regular use of antipyretic or analgesic medication on a daily or every other day basis; notes: a daily dose of 81 mg of aspirin is not considered a contraindication to enrollment. discontinuation of prophylactic use of antipyretic or analgesic medications at the time of enrollment and for fourteen days following vaccination is not considered a contraindication to enrollment. * pregnancy or, in biologically capable women (e.g., menses within the last year) participant does not agree to use acceptable birth control measures as determined by the investigator continuously for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result); * breastfeeding or lactating women; * administration of intranasal medications within two weeks prior to enrollment or expected receipt during this study; * employees of the investigational site or their family member or any individuals involved with the conduct of the study; and * any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.
intestinal microbiota and chronic fatigue syndrome

Conditions: Fatigue Syndrome, Chronic; Microbial Colonization

Summary: gut microbiota of 1) patients with chronic fatigue syndrome and 2) their healthy family members are analyzed. up to 40 patients with chronic fatigue syndrome are randomized to receive either 1) a faecal transplant from a healthty donor or 2) their own feces via colonoscopy. patient's health related quality and ability to work are assessed (baseline, 1 and 6 months after the procedure)

patients with chronic fatigue syndrome (cfs) and their healthy family members (living together in the same house) are recruited in the study. cfs has been diagnosed in tampere university hospital and the diagnosis is based on thorough clinical assessment fulfilling the institute of medicine 2015 criteria. patients microbiota is analyzed (microbiological analysis, mediators of inflammation) and results are compared with their family members. via colonoscopy, up to 40 patients with cfs are randomized to receive either a faecal transplant from a healthy donor (treatment group) or his/her own feces (placebo group). products are blinded, investigators and patients are blinded. patients' health related quality of life and ability to work or study are assessed (baseline, 1 and 6 months after the procedure).

Eligibility criteria:
inclusion criteria: -chronic fatigue syndrome exclusion criteria: * other conditions causing chronic fatigue * diseases affecting the intestinal system

Keywords: fatigue microbiome
zenith thoracic alpha (zta) post-market data collection

Conditions: Thoracic Aortic Aneurysm; Penetrating Aortic Ulcer

Summary: this study aims to gather real-world clinical data demonstrating the continued safety and performance of the a marketed stent graft (zenith® alpha thoracic endovascular graft \[zta\]) and collect longer term follow-up to better understand clinical outcomes associated with the expected lifetime of the device.

per local regulations, this study includes both retrospective and prospective patients. patients can be included retrospectively if they are treated with the study device from 01 january 2019 until the study site is eligible for prospective enrollment.

Eligibility criteria:
inclusion criteria: * patient has been treated/was intended to be treated with zta according to the clinical practice from jan 2019 until site initiation * the patient is willing to participate in the study and provide written informed consent for study participation or express non-objection or give written consent per local requirements prior to data collection of any data from medical records. exclusion criteria: * a patient treated with a custom-made fenestrated and/or branched endovascular graft in conjunction with zta either during the same procedure or in a staged procedure. * a patient whose follow-up data collection is not possible (e.g. due to living abroad).

Keywords: aneurysm thoracic descending aorta stent-graft
neoadjuvant chemotherapy versus radiochemotherapy for cancer of the esophagus or cardia

Conditions: Carcinoma, Squamous Cell; Adenocarcinoma of the Esophagus and Gastric Cardia

Summary: the purpose of this randomized study is to clarify if neoadjuvant radiochemotherapy gives a higher degree of complete histological response than neoadjuvant chemotherapy before surgery in patients undergoing treatment for cancer of the esophagus or cardia.


Eligibility criteria:
inclusion criteria: * histologically verified squamos cell carcinoma, adenocarcinoma of the esopohagus or gastric cardia (type ii) * tumor located in cervical oesophagus, not requiring laryngo-esophagectomy. patients with performance status 0-1 axxording to who scale and with resectable tumours, as assessed at the prerandomisation evaluation * adequate haemotological function, defined as having wbc \> 3 x 10(9)/litre and platelets \> 100 x 10 (9)/litre. * adequate renal function defined as having normal serum creatinine level and/or calculated glomerular filtration rate \> 60 ml/min. * tumour stage: t1ni, t2n0, t2n1, t3n0, t3n1, m1a exclusion criteria: * pregnancy and/or lactation. women of childbearing ages can be included and provided that adequate contraceptive methods are used * patients with diabetes complications (e.g. rethinopathy, neuropathy) as well as patients with uncontrolled cardiac disease or myocard infarction within 12 months are considered unsuitable for chemoradiotherapy. * concomitant malignancy (\< 5 years since diagnosis) that can interfere the interpretation of study results, ongoing antitumoral treatment. * patients being unable tom comply with the protocol * tumor stage t1 n0, t4 nx or txnxm1b

Keywords: histologically confirmed squamos cell carcinoma or adenocarcinoma of the esophagus and gastric cardia.suitable for surgery.
efficacy and safety study of the tolvaptan tablets in patients with non-hypovolemic non-acute hyponatremia

Conditions: Non-hypovolemic Non-acute Hyponatremia

Summary: this drug has been developed to treat hyponatremia. the primary purpose of this study is to verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15, 30, and 60 mg or placebo in patients with non-hypovolemic non-acute hyponatremia secondary to congestive heart failure (chf), hepatic cirrhosis or syndrome of inappropriate antidiuretic hormone (siadh), despite receiving standard therapy. this study is being conducted in china.


Eligibility criteria:
inclusion criteria (for chf): 1. patients with chf who exhibit edema, jugular venous distention, hepatomegaly, or pulmonary congestion. 2. non-hypovolemic and non-acute hyponatremia with a serum sodium \< 135meq/l before randomization. 3. patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period. 4. patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration. 5. age:18～80 (when informed consent is obtained)，male or female. 6. in-patient subjects. 7. informed consent. inclusion criteria (for hepatic cirrhosis): 1. patients with hepatic edema. 2. non-hypovolemic and non acute hyponatremia with a serum sodium \< 135meq/l before randomization. 3. age:18～65 (when informed consent is obtained)，male or female. 4. in-patient subjects. 5. informed consent. inclusion criteria (for siadh and others): 1. patients with siadh arising from a variety of etiologies. 2. non-hypovolemic and non acute hyponatremia with a serum sodium \< 135meq/l before randomization. 3. age:18～80 (when informed consent is obtained)，male or female. 4. in-patient subjects. 5. informed consent.

Keywords: hyponatremia non-hypovolemic and non-acute hyponatremia tolvaptan
the measurement of nocturnal hypokinesia in parkinson's disease (pd) patient compared with spouse by wearable sensors

Conditions: Parkinson Disease

Summary: to quantitative measurement of nocturnal hypokinesia of parkinson's disease patients compares with their spouses by using multisite accelerometers for 1 night at their home. to determine whether the nocturnal movement of parkinson's disease patients less than normal elderly people or not.

to quantify the severity of nocturnal akinesia, the nocturnal akinesia dystonia and cramp score (nadcs) and unified parkinson's disease rating scale (updrs) were recorded in the patient group and also details of demographic data, history and physical examinations were included. the patients and spouses wore the 3-axis (x,y,z) accelerometers at bilateral wrists, bilateral ankles, and trunk for 1 night at their home. the 5-minute periods after going to bed and before waking up in the morning were excluded from the analysis. the definition of movement of the trunk is a change of 15 degrees from the previous position and sustained for 5 minutes in any axis. the movement of limbs is defined as a change of 15 degrees from the previous position and sustained for 2 minutes.

Eligibility criteria:
inclusion criteria: * parkinson's disease patients who met the criteria diagnosis of united kingdom parkinson's disease society brain bank (ukpdsbb) with their spouses which age difference less than 10 years. exclusion criteria: * 1) patients and/or spouses who were bed ridden, * 2) a history of other neurological diseases or other muscle and joint diseases, * 3) no history of hypnotic drug use

Keywords: nocturnal hypokinesia accelerometers
a trail of a novel tracheal radioactive stent for the malignant airway obstruction

Conditions: Malignant Airway Obstruction

Summary: the aim of this study was to evaluate the safety and effectiveness of an radioactive airway stent loaded with 125i seeds compared to a conventional airway stent in patients with malignant airway obstruction caused by both primary and metastatic malignant tumors.

malignant tumors of the lung, esophagus, thyroid, or other mediastinal structures often involve the trachea by direct tumor growth compression and (or) invasion. in addition, extrathoracic cancers metastasize to these lymph nodes as well. however, surgical resection and airway reconstruction are the gold-standard treatment for mao, many patients with airway involvement are poor surgical candidates based on physiologic or oncologic criteria.there are three main types of malignant airway obstruction: endobronchial obstruction, extrinsic compression, and a mixed pattern. for endobronchial obstruction, ablative techniques that destroy tissue are indicated, including lasers, electrocautery, argon plasma coagulation (apc), photodynamic therapy, microdebriders, and cryotherapy, but primary tracheal cancers are less common than other types of lung cancer. if the obstruction is exclusively or mainly due to compression from outside the airway wall, the only option consists of placement of a stent or endoprosthesis. however, follow-up data has demonstrated that postoperative restenosis of stenting occurs in 5-45% of cases as a result of neoplastic infiltration through the mesh into the lumen or tumor overgrowth above and below the mesh stents. encouraged by the success of 125i esophageal and biliary stent in esophageal carcinoma , a tracheal stent loaded with 125i radioactive seeds was developed in investigators'institute. after successful in vitro and in vivo evaluations of the delivery system, investigator will prospectively compare responses to treatment with this irradiation tracheal stent versus the conventional self-expandable stent in patients with mao.

Eligibility criteria:
inclusion criteria: 1. aged between 18 and 80 years 2. mao caused by any adenocarcinoma with histologically or cytologically confirmation by biopsy or previous surgical procedures 3. symptoms such as dyspnea related to biliary obstruction 4. unresectability or refusal to be surgically treated 5. willing and able to comply with the study procedures and provide written informed consent to participate exclusion criteria: 1. patients with suspected benign airway obstruction 2. airway obstruction that could not be dilated enough to pass the delivery system 3. perforation of any ducts within the tracheal tree 4. presence of metallic tracheal stent or airway surgery 5. acute or chronic inflammation in the airway 6. uncooperative or could not provide authorization and signature.

Keywords: trachea stent intraluminal brachytherapy
exoskeleton neurogenic bowel dysfunction study

Conditions: Spinal Cord Injuries; Neurogenic Bowel

Summary: the purpose of the study is to assess the effects of exoskeleton training on neurogenic bowel disorders in spinal cord injury/ disease.

after being informed about the study and the potential risks, all patients giving written consents will undergo a medical examination to ensure they are eligible and fit to proceed for the study. subjects will be randomly assigned to intervention group and control group. intervention group will receive 2 consecutive courses of exoskeleton training (et) with twelve 45-minute sessions, each to be completed in 6 to 8 weeks. the total period of training will be 12 to 16 weeks. control group will receive twelve 45-minute sessions of usual physiotherapy treatment (pt), consisting of maintenance exercise in the first 6 to 8 weeks, and then one course of et with twelve 45-minute sessions in the following 6 to 8 weeks.

Eligibility criteria:
inclusion criteria: 1. sci/d for a duration ≥ 12 months 2. neurological level of injury (nli) c4 to l3 as defined in the international standards for neurological classification of spinal cord injury (isncsci) 2019 revision 3. bowel opening via anal route or stoma 4. stable medical condition 5. stable mental condition 6. no active painful musculoskeletal problems like fracture, infection, pressure injury, contracture or uncontrolled spasticity 7. age ≥ 18 years old 8. body height 150 - 188cm exclusion criteria: 1. unstable cardiovascular or pulmonary conditions 2. untreated thromboembolic events 3. untreated psychiatric disorders 4. history of malignancy 5. any contra-indications for exoskeleton training

Keywords: spinal cord injuries neurogenic bowel exoskeleton rehabilitation
outcome of bilateral thoracoscopic sympathectomy for patients with primary focal hyperhidrosis

Conditions: Hyperhidrosis Primary Focal Palms

Summary: the goal of this clinical trial is to examine the overall efficiency of bilateral thoracoscopic sympathectomy on the permanent reduction of primary focal hyperhidrosis of predilective parts of the body, palms, armpits, face, and soles.

the aims of this study are: 1. examine the efficiency of bilateral thoracoscopic sympathectomy (bts) with different levels of transection among the persons with the primary focal hyperhidrosis (pfh) 2. examine the influence of bts on cardio-pulmonary function tests in persons with pfh after the operation. 3. examine the incidence, duration, and intensity of compensatory sweating after bts among persons with pfh 4. examine the incidence, duration, localization, and treatment of postoperative pain after bts among persons with pfh. 5. determine postoperative complications of bts among persons with pfh 6. examine the influence of bts on quality of life among persons with pfh

Eligibility criteria:
inclusion criteria: * a. persons with confirmed and estimated primary focal hyperhidrosis accepted to participate in this investigation, fulfilling pre and postoperative questionnaires about bts effects and quality of life after the operation * b. satisfactory cardiopulmonary function exclusion criteria: * previous thoracic surgical procedures, rib fractures, massive pneumonias, or pleural empyema * secondary hyperhidrosis

Keywords: hyperhidrosis primary focal hyperhidrosis